Navigation Links
Atlanta-based Med Tech Company CardioMEMS Raises Additional Capital to Advance its CHAMPION Clinical Trial for its Wireless Sensor System for Heart Failure Monitoring
Date:8/26/2009

ATLANTA, Aug. 26 /PRNewswire/ -- CardioMEMS, Inc., a medical technology company that has developed and is commercializing proprietary wireless sensing and communication technology for the human body, today announced the completion of a $22.1M financing. The financing provides the company with additional capital to fund the company's CHAMPION clinical trial. Initiated in September 2007, the CHAMPION trial is evaluating the safety and effectiveness of CardioMEMS' heart failure (HF) pressure measurement system in patients with heart failure.

The CardioMEMS wireless HF sensor is an innovative miniature device which is implanted into the patient's pulmonary artery using a simple, catheter-based procedure. The pulmonary artery pressure is then measured and displayed using the CardioMEMS proprietary electronic monitoring system. Following the procedure, patients perform wireless measurements of their pulmonary artery pressure from home. The pressure data is immediately transmitted to a secure database and is available for review by the implanting physician on the CardioMEMS proprietary website.

The CHAMPION clinical trial is being conducted in over 65 leading heart centers in the U.S. The co-principal investigators of the trial are Philip Adamson, MD, Director of the Heart Failure Institute, Oklahoma Heart Institute and William Abraham, MD, Director of the Division of Cardiovascular Medicine at The Ohio State University Medical Center.

Jay Yadav, MD, Chairman and CEO of CardioMEMS and an interventional cardiologist, commented, "We are excited about our heart failure technology and the potential benefits that are available to patients who have this serious condition. This is a very exciting time for CardioMEMS and we are looking forward to the great opportunities in front of us in 2010."

Commenting on the financing, Dan Bauer, CardioMEMS CFO stated, "We are pleased with the continued support of Arcapita Ventures, Boston Millennium, Foundation Medical and our other existing investors. We look forward to the successful completion of the CHAMPION trial as well as pursuing other opportunities where our technology can be beneficial." CardioMEMS anticipates seeking FDA approval of its CHAMPION heart failure pressure measurement system in 2010. In the U.S. alone, there are approximately 5.5 million heart failure patients.

CardioMEMS is located in Atlanta, GA and is privately held. More information about the company can be found at www.cardiomems.com.

About CardioMEMS, Inc.

CardioMEMS is a medical device company that has developed and is commercializing proprietary wireless sensing and communication technology for the human body. Our technology platform is designed to improve the management of severe chronic cardiovascular diseases such as aneurysms, heart failure and hypertension. Our miniature wireless sensors can be implanted using minimally-invasive techniques and transmit cardiac output, blood pressure and heart rate data which are critical to the management of patients. Our sensors are designed to be permanently implanted into the heart and blood vessels due to their small size, durability, and lack of wires and batteries. Using radiofrequency, or RF, energy, our sensors transmit real-time data to external electronic readers which then communicate this information to the patient's physician. We believe frequent, on-demand, real-time monitoring of vital information enables proactive patient management, which holds the promise of reducing hospitalizations, improving a patient's quality of life and delivering more efficient and cost effective health care.

Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, expected timing or results of any clinical trials, ultimate clinical outcome and perceived or actual advantages of the Company's products, market and physician acceptance of the products, intellectual property protection, and competitive offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.

CardioMEMS is a registered trademark of CardioMEMS, Inc.


'/>"/>
SOURCE CardioMEMS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
2. Karolinska Development Portfolio Company Launches GMP Facility for Particulate Manufacturing
3. European Division of Global Top 20 Pharmaceutical Company Awards Phase III Trial to DATATRAK
4. Infant Formula Company Teams With the University of Virginia Pediatrics Department to Conduct Clinical Studies
5. Ethicon Endo-Surgery Studies Presented at DDW Demonstrate Potential of Pure NOTES Surgery With Companys Toolbox
6. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
7. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
8. Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments
9. BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference
10. Access Pharmaceuticals Presents new Combination Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
11. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... Aug. 7, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Saban as president, effective Aug. 7, 2017. ... decided to pursue other interests and will serve as president ... Paul has served us in multiple leadership roles since he ... Jun. 2015 and has provided decisive, strategic leadership which continues ...
(Date:8/7/2017)... 2017  Endo International plc (NASDAQ: ENDP ... virtually all known U.S. mesh product liability claims and ... known remaining U.S. claims at reasonable values. Under the ... fourth quarter of 2017 and continuing through the fourth ... 2017 results, the Company intends to increase its mesh ...
(Date:8/4/2017)... CINCINNATI , Aug. 3, 2017  Agragen, ... science company active in the biopharmaceutical, nutraceutical, and ... its development of its lead drug candidates, AGR131.  ... a proinflammatory cytokine from the blood of patients ... psoriasis, and inflammatory bowel disease. ...
Breaking Medicine Technology:
(Date:8/20/2017)... , ... August 20, 2017 , ... ... HIPAA ComplyPAK™ Compliance Management System has assisted multiple clients in successfully ... Public Accountants, Service Organization Control Level 2 (AICPA SOC Level 2), and State ...
(Date:8/19/2017)... ... August 19, 2017 , ... ... will feature the Aurum Group in an upcoming episode, slated to air fourth ... Innovations will feature the Aurum Group; a company committed to supporting dentistry using ...
(Date:8/19/2017)... ... August 18, 2017 , ... ... Act of 2017, legislation that provides for greater public access to over-the-counter (OTC) ... loss to access OTC hearing aids without being seen by a certified and ...
(Date:8/19/2017)... ... August 19, 2017 , ... Praeclarus Press has launched a ... show the diversity of the breastfeeding mothers, using bright colors and contemporary ... These illustrations are also available on tote bags, notepads, smartphone cases, clocks, and ...
(Date:8/19/2017)... ... August 19, 2017 , ... Physician ... its Orlando location as an interventional pain management physician. He brings a wealth ... treatment of migraine headaches, and significant experience in spinal cord stimulation for chronic ...
Breaking Medicine News(10 mins):